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Abstract
Columnar cell hyperplasia (CCH) is the earliest histologically identifiable breast lesion linked to cancer progression and is
characterized by increased proliferation, decreased apoptosis and elevated oestrogen receptor a (ERa) expression. The
mechanisms underlying the initiation of these lesions have not been clarified but might involve early and fundamental
changes in cancer progression. MiRNAs are key regulators of several biological processes, acting by influencing the post-
transcriptional regulation of numerous targets, thus making miRNAs potential candidates in cancer initiation. Here we have
defined novel epithelial as well as stromal miRNA signatures from columnar cell hyperplasia lesions compared to normal
terminal duct lobular units by using microdissection and miRNA microarrays. Let-7c were among the identified
downregulated epithelial miRNAs and its functions were delineated in unique CCH derived cells and breast cancer cell line
MCF-7 suggesting anti-proliferative traits potentially due to effects on Myb and ERa. MiR-132 was upregulated in the stroma
surrounding CCH compared to stoma surrounding normal terminal duct lobular units (TDLUs), and overexpression of miR-
132 in immortalized fibroblasts and in fibroblasts co-cultured with epithelial CCH cells caused substantial expression
changes of genes involved in metabolism, DNA damage and cell motility. The miRNA signatures identified in CCH indicate
early changes in the epithelial and stromal compartment of CCH and could represent early key alterations in breast cancer
progression that potentially could be targeted in novel prevention or treatment schedules.
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Introduction
The initial model of the evolution of breast cancer was proposed
to be a long process involving a few key stages, starting with
proliferation and enlargement of the normal terminal duct lobular
units (TDLUs) [1]. These alterations, denoted columnar cell
hyperplasia (CCH), are common abnormalities in the adult female
breast and are characterized by enlarged TDLUs lined by tightly
packed columnar-shaped epithelial cells [2,3]. The structures,
referred to as atypical lobule of type A by Wellings, were suggested
to represent the first precursor to ductal carcinoma in situ [1].
This assumption was later supported by associations between
CCH and more advanced stages of breast carcinoma [2,4,5].
Characteristic features are increased number of oestrogen receptor
a (ERa) positive cells, increased proliferation and decreased
apoptosis [3], but the underlying mechanism of these changes has
not been fully delineated.
The interplay between epithelial cells and the stromal
compartment plays a significant role in breast development and
cancer progression. Moreover, abnormal interactions between
these compartments already at stages of early premalignant lesions
of the breast have been suggested [6,7]. The microenvironment
consists of extra-cellular matrix (ECM) and different cell types
including fibroblasts. These principal cellular components in the
stroma are crucial in maintaining ECM homeostasis by synthe-
sising and regulating degradation of the fibrillar components of the
ECM. It is possible to observe changes in the stroma in early stages
of cancer development, including an increased number of
fibroblasts which have acquired an active phenotype that is also
PLOS ONE | www.plosone.org 1 August 2014 | Volume 9 | Issue 8 | e105099
observed in wound healing [8]. These cells are commonly called
cancer-associated fibroblasts and can promote tumour growth and
progression [9].
MicroRNAs (miRNAs) are ,21 nt long endogenous non-
coding RNAs that regulate gene expression in a post-transcrip-
tional manner mainly by interacting with the 39UTR of their
target mRNAs [10]. They play important roles during develop-
ment, are involved in most cellular processes and have been
implicated in cancer initiation and progression [11].
In this study we have identified miRNA expression signatures in
both the epithelial and stromal compartment of CCH compared
to TDLU that could represent key alterations in early breast
cancer progression.
Results
CCH have altered miRNA expression patterns
TDLUs and CCH with no or mild atypia from the same
specimen were collected based on morphological evaluation and
positive ERa expression using microdissection. Sufficient material
for array analysis from epithelial cells (n = 4) and surrounding
stroma (n= 2) were collected and RNA was isolated (Figure 1).
MiRNA array analysis yielded expression data from 663 miRNAs.
By comparing the expression in TDLUs and CCH we discovered
23 altered miRNAs in the epithelial compartment (n = 4, p,0.05,
Table 1) and 17 in the surrounding stroma (n= 2, more than 2.0
fold change, Table 2). After moderating for false discovery rate,
the number of significantly altered epithelial miRNAs decreased to
two. Most miRNAs, 22 in the epithelial compartment and 14
stroma, were downregulated. The selected epithelial and stromal
miRNA in this study was downregulated and upregulated,
respectively, in CCH compared to TDLU.
Involvement of let-7c in epithelial CCH features
Epithelial cells in CCH lesions have elevated ERa expression,
decreased apoptotic rate and increased proliferation compared to
cells in TDLUs [3]. We chose to study the involvement of one
selected miRNA, let-7c, in the regulation of these characteristics in
CCH. Let-7c was chosen from the array data based on previous
reports linking it both to proliferation and apoptosis [12,13]. Let-
7c was also predicted to target the transcription factor Myb that
was previously shown to be upregulated in CCH lesions [14]. We
used cells derived from CCH lesions and the ER positive breast
cancer cell line MCF-7. The CCH cells were chosen based on
their origin and MCF-7 was selected as a model for ER positive
epithelial cells at a more progressed stage and expressed lower
Figure 1. Characteristics of TDLU and CCH, and laser capture microdissection. Tissues were fixed in formalin, embedded in paraffin,
sectioned and immunohistochemically stained with hematoxylin and eosin. Selected specimens were stained for ERa as additional control for the
selection of the lesions. A) Identification of TDLU (arrow head) and CCH (arrow) based on morphology (microscopic evaluation) (20X). B) ERa
expression in TDLU and CCH (20X). C–H) Images of TDLU (upper panel C–E) and CCH (lower panel F–H) before (C, F) and after laser capture
microdissection (LCM) of epithelia (D, G) and stroma (E, H) (40X).
doi:10.1371/journal.pone.0105099.g001
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levels of let-7c compared to the CCH cells. (Figure 2 and figure
S1) The decreased expression of let-7c was confirmed in one
additional patients using microdissection and qRT-PCR (figure
S2). Using miRNA inhibitors and mimics, we modulated the
expression levels of let-7c in the CCH and MCF-7 cells
(Figure 3A–B). We observed that decreased levels of let-7c in
CCH cells significantly increased the number of cells whereas the
opposite effect was observed after let-7c overexpression (p= 0.050
and p=0.041, respectively, Figure 3C). This was confirmed in
MCF-7 cells where an increased expression of let-7c significantly
decreased the number of cells and the proliferation rate measured
by Alamar Blue (p = 0.005 and p= 0.035, respectively, Figure 3D).
However, we did not detect any significant differences in S-phase
ratio after modulation of let-7c levels.
In order to see if the observed effects on cell number were
indeed a measurement of proliferation, we investigated the
possible involvement of apoptosis. We did not observe the
apoptotic marker cleaved caspase 3 in the CCH cells after let-7c
overexpression (Figure 4A), nor did we observe any differences in
either early apoptosis (Annexin V+/7AAD–cells) or late apoptosis
(Annexin V+/7AAD+cells) in MCF-7 cells (Figure 4B).
Links between let-7c, Myb and ER
In order to investigate possible gene targets for let-7c, we used
gene expression data from a previous study comparing epithelial
gene expression differences between epithelial cells in TDLUs and
CCH [14]. The data was related to potential target sites for let-7c
using a target prediction algorithm [15,16]. Interestingly, the
transcription factor Myb, which had elevated levels in CCH in the
reported study, displayed a potential target site for let-7c (data not
shown). In line with that, we detected lower levels of Myb in the
CCH cells compared to MCF-7 cells (p,0.001, Figure 5A). In
order to investigate the relation between let-7c and Myb
expression, we modulated the levels of let-7c and monitored the
levels of Myb mRNA. Decreased expression of let-7c resulted in
significantly increased levels of Myb mRNA in the CCH cells
(p = 0.024), and the opposite was observed after upregulation of
let-7c in both CCH cells and MCF-7 cells (p = 0.021 and 0.018,
respectively). A similar pattern was also observed for ERa
(p = 0.070) after overexpression of let-7c, and the link between
Myb and ERa is well-established (Figure 5B) [17,18]. We also
detected elevated protein levels of Myb and ERa in MCF-7 cells
after downregulation of let-7c, and the opposite effect after
upregulation of let-7c (Figure 5C). In addition, we detected
elevated Myb protein expression in CCH lesions compared to
normal TDLUs in human mammary tissue, validating the
experimental in vitro findings in vivo and are in agreement with
the published data [14] (Figure 5D).
Table 1. MiRNA expression signatures in epithelial and stromal compartments of CCH compared to TDLU.
Epithelial cells (n = 4) Fold change (log 2) P{ q-value (FDR)
hsa-miR-625 20.79 ,0.001 0.046
hsa-miR-455-5p 21.75 0.001 0.046
hsa-miR-532-3p 20.78 0.004 0.061
hsa-miR-92a 21.46 0.004 0.061
hsa-miR-886-3p 21.43 0.006 0.061
hsa-let-7c 21.17 0.006 0.061
hsa-miR-383 22.36 0.007 0.061
hsa-miR-505* 21.02 0.010 0.083
hsa-miR-150 21.34 0.017 0.086
hsa-miR-29b 21.04 0.017 0.086
hsa-miR-27a 20.93 0.017 0.086
hsa-miR-491-5p 21.35 0.017 0.086
hsa-miR-190b +1.61 0.014 0.086
hsa-miR-130a 21.18 0.021 0.094
hsa-miR-886-5p 21.26 0.025 0.094
hsa-miR-204 21.30 0.026 0.094
hsa-let-7f 21.54 0.028 0.094
hsa-miR-335* 21.23 0.022 0.094
hsa-miR-20a* 21.20 0.027 0.094
hsa-miR-135a* 20.63 0.029 0.094
hsa-miR-494 21.24 0.040 0.125
hsa-miR-26b* 21.14 0.043 0.128
hsa-miR-29c 20.87 0.046 0.129
Results are presented as log2 fold change.
{P was calculated using paired two-sided Student’s t-test.
The false discovery rate (FDR) was calculated from the p-values of the 137 miRNAs whose fold changes between the two conditions were greater than 1.5 and is
presented as q-values.
doi:10.1371/journal.pone.0105099.t001
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Interactions between epithelial and stromal
compartments
The almost 3-fold increase of miR-132 in the stroma
surrounding CCH lesions is interesting due to the essential role
of stromal miR-132 in the development of ductal structures in
mouse mammary glands [19]. We therefore increased the levels of
miR-132 in human mammary fibroblasts and performed gene
expression array analyses. The top ten up- and downregulated
gene candidates are presented in table 3 and include FBN3,
COL9A1 and UBE3A. Several of the identified gene candidates
were involved in pathways regulating metabolism, DNA damage
response, cell motility and the cytoskeleton.
To investigate whether elevated levels of miR-132 in the stroma
also affected human mammary epithelial cells, we co-cultured
epithelial CCH cells with fibroblasts overexpressing miR-132 and
performed gene expression array analysis of the epithelial cells
(Table 4). Interestingly, we observed approximately 450 signifi-
cantly altered genes including metabolic genes (GLUL, ACSS2,
DHRS9), genes involved in protein turn-over (MARCH9,
CUL4B), genes implicated in the cytoskeleton and cell motility
(IFFO1, DOCK5), genes encoding cell cycle regulatory proteins
(NEK11, NEK9), as well as genes related to the main features of
CCH: proliferation (RASGRP3), apoptosis (WNK3) and ERa
expression (GLUL). The pathway analysis further revealed that
pathways involved in cytoskeleton and tight junction signalling via
isoforms of the myosin heavy chain (MYH) gene were upregulated.
Case study – progression of TDLU via CCH to invasive
breast cancer
To further illustrate the fluctuation of miRNA levels in breast
cancer progression, we analysed the miRNA expression profile of
the epithelial and stromal compartments of another patient who
displayed invasive breast cancer (IBC) in addition to TDLUs and
CCH. Initially, we examined whether the selected miRNAs
Table 2. MiRNA expression signatures in the stromal compartment of CCH compared to TDLU.
Stroma (n = 2) Fold change (log 2)`
hsa-miR-539 +4.82
hsa-miR-132 +2.61
hsa-miR-221 +2.34
hsa-miR-135b 22.15
hsa-miR-451 22.19
hsa-miR-642 22.23
hsa-miR-130b 22.32
hsa-miR-20a 22.35
hsa-miR-204 22.35
hsa-miR-192 22.40
hsa-miR-29b 22.43
hsa-miR-452 22.48
hsa-miR-124 22.84
hsa-miR-95 22.94
hsa-miR-423-5p 22.97
hsa-miR-148a 22.98
hsa-miR-139-3p 23.40
Results are presented as log2 fold change.
`A fold change $2.0 was used as cut-off.
doi:10.1371/journal.pone.0105099.t002
Figure 2. Characteristics of CCH and MCF-7 cells. A) Baseline
endogenous levels of let-7c were lower in CCH cells compared to MCF-7
cells, modelling the observed levels in TDLU and CCH in patients (n = 2,
p = 0.072). B) CCH cells were ER-negative and combined luminal and
basal epithelial phenotypes (80X).
doi:10.1371/journal.pone.0105099.g002
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followed the observed pattern noticed in CCH lesions (Figure 6A).
The expressions of the epithelial miRNA let-7c continued to
decrease in IBC, whereas the expression level of the stromal miR-
132 in the IBC was even lower than in the stroma surrounding
normal TDLUs suggesting that in this case, miR-132 was only
overexpressed in the early precancerous lesion.
We also investigated if there was a tendency for a certain
expression pattern to be predominant in the progression towards
IBC and plotted the fold change expressions for all miRNA as
illustrated in figure 6B. The two most common patterns in both
the epithelial and stromal compartment were progressive decrease
in miRNA expression (TDLU.CCH.IBC) including 19% of all
miRNAs in the epithelia and 24% in the stroma, and downreg-
ulation of the miRNA in CCH with a similar level in IBC
(TDLU.CCH= IBC) comprising 25% in the epithelia and 16%
in the stroma. We also observed a more than 10-fold increased
expression of miR-652 in the epithelial compartment and of miR-
484 in the stromal compartment of the sample with invasive breast
cancer.
Discussion
By using microdissection we have identified differences in
miRNA expression in both epithelial and stromal compartments of
CCH, the proposed lesion to be the first histologically recognizable
alteration in the progression towards breast cancer, compared to
TDLU. The main findings are summarized in figure 7. The
majority of miRNAs were downregulated, which could possibly
explain the overall upregulation of genes observed by Lee et al in
epithelial CCH cells in vivo [14]. Among the identified downreg-
ulated miRNAs in the epithelial compartment was let-7c which
appeared to play a role in one of the main characteristics of CCH;
increased proliferation. Let-7c has been reported to be downreg-
ulated in pancreatic cancer, and in prostate cancer it has the
ability to inhibit growth both in vitro and in vivo [12,20]. We
observed that let-7c had anti-proliferative properties but was not
involved in apoptosis as previously described [13]. One of the
in silico predicted targets for let-7c was the proliferation promot-
ing transcription factor Myb which has been shown to be
overexpressed in colon and breast cancer and our experimental
data support the notion that let-7c has a negative effect on Myb
Figure 3. The effect of let-7c on proliferation in CCH cells and MCF-7 cells. Modulation of miRNA levels by A) inhibitors and B) mimics was
validated and confirmed by qRT-PCR. C) Proliferation measured by cell count performed in CCH cells after miRNA level alteration. D) Proliferation
measured by cell count, Alamar Blue and cell cycle analysis (S-phase ratio) in MCF-7 cells after miRNA level alteration. All results are calculated using
two-sided paired t-tests and presented as mean plus standard deviation, n = 3.
doi:10.1371/journal.pone.0105099.g003
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Figure 4. The effect of let-7c on apoptosis in CCH cells and MCF-7 cells. A) Apoptosis analysis of CCH cells after alteration of miRNA levels
measured by cleaved caspase 3 protein expression and Western blot analysis. CCH cells treated with 1 mM staurosporine were used as a positive
control for apoptosis. B) Early (Annexin V+/7AAD–) and late (Annexin V+/7AAD+) apoptosis was measured using flow cytometry in MCF-7 cells (n = 3).
doi:10.1371/journal.pone.0105099.g004
Figure 5. Associations between let-7c and Myb and ERa. A) Endogenous Myb mRNA levels, measured by qRT-PCR in CCH and MCF-7 cells.
Results are calculated using two-sided unpaired t-test and presented as mean plus standard deviation, n.3. B) Myb mRNA levels were measured with
qRT-PCR after up- and downregulation of let-7c in CCH cells and MCF-7 cells. ERa mRNA was measured in MCF-7 cells after let-7c modulation. Results
are calculated using two-sided paired t-tests and presented as mean plus standard deviation, n = 3. C) Myb and ERa protein expression measured by
Western blot after let-7c downregulation and upregulation. The figure shows representative blots from one of three independent experiments. D)
Protein expression of Myb in TDLU and CCH (80X).
doi:10.1371/journal.pone.0105099.g005
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mRNA and protein expression in both CCH cells and MCF-7 cells
[21]. We also observed similar effects on ERa, which could
explain the noticed effects on Myb in MCF-7 [17,18]. However,
the in silico miRNA target prediction algorithm did not predict
let-7c to target ERa, and the CCH cells are ER negative,
suggesting that let-7c can probably indirectly affect both Myb and
ERa independently. Based on these results, one could conclude
that let-7c has negative effects on cell proliferation and a most
likely indirectly negative effect on Myb and ERa expression,
however the exact link remains to be investigated.
In the stromal compartment, we observed an increase of miR-
132. This is interesting since stromal miR-132 is crucial in the
development of the mouse mammary gland [19]. By overexpress-
ing miR-132 in fibroblasts, we indeed observed several changes.
Among the identified upregulated candidate genes was UBE3A.
UBE3A is an E3 ubiquitin ligase targeting the CDK inhibitor p27
in mouse brain, and downregulation of UBE3A led to cell cycle
arrest [22]. This effect on proliferation can possibly link UBE3A to
the increased proliferative rate of cancer-associated fibroblasts
observed in prostate cancer [23]. Additionally, one of the altered
pathways was ‘‘Pancreatic Adenocarcinoma Signalling’’ which is
in line with previous studies associating pancreas cancer and miR-
132 [24,25]. To see if the increased expression of miR-132 in the
stroma had any effect on the epithelial CCH cells, we tried to
mimic this scenario by overexpressing miR-132 in fibroblasts and
then co-cultured them with epithelial CCH cells followed by gene
expression of the epithelial cells. Among the altered genes were
GLUL, WNK3 and RASGRP3. They have all respectively been
Table 3. Gene expression analysis of miR-132 overexpressing fibroblasts.
10 most upregulated genes
Fold change
(log2)
10 most
downregulated
genes Fold change (log2)
IQCH 3.91 GART 21.87
UBE3A 3.32 LUZP2 21.85
FBN3 2.92 PXK 21.83
INTS2 2.82 USP34 21.82
NLRP3 2.72 APC2 21.80
RRM2 2.69 NFE2L2 21.79
COL9A1 2.67 MYO5C 21.77
ARID4A 2.65 KIAA1324 21.76
SFMBT1 2.60 GBAS 21.75
AIM1 2.49 TFIP11 21.72
Top 10 upregulated pathways P{ Ratio ` Genes
Hereditary Breast Cancer Signaling 0.003 3/129 FANCM, PIK3C2G, FANCC
Fatty Acid Metabolism 0.003 3/184 ACADSB, ACADM, CYP3A5
b-alanine Metabolism 0.006 2/93 ACADSB, ACADM
Role of BRCA1 in DNA Damage Response 0.009 2/61 FANCM, FANCC
Propanoate Metabolism 0.009 2/121 ACADSB, ACADM
Valine. Leucine and Isoleucine Degradation 0.011 2/106 ACADSB, ACADM
Role of Pattern Recognition Receptors in
Recognition of Bacteria and Viruses
0.016 2/87 NLRP3, PIK3C2G
TR/RXR Activation 0.019 2/96 NCOA2, PIK3C2G
Estrogen Receptor Signaling 0.040 2/136 NCOA2, ESR2
AMPK Signaling 0.043 2/167 PIK3C2G, PFKFB2
Top 10 downregulated pathways P{ Ratio ` Genes
Molecular Mechanisms of Cancer 0.003 8/377 SMAD2, PAK3, PRKAR2A, MDM2, RALBP1, RASA1, RALGDS,
FNBP1
Regulation of Actin-based Motility by Rho 0.003 4/91 WASL, PAK3, BAIAP2, FNBP1
Actin Cytoskeleton Signaling 0.005 6/238 MYH6, WASL, PAK3, APC2, DIAPH3, BAIAP2
Pancreatic Adenocarcinoma Signaling 0.007 4/119 SMAD2, MDM2, RALBP1, RALGDS
Mitotic Roles of Polo-Like Kinase 0.010 3/64 SLK, PPP2CB, CDC16
Angiopoietin Signaling 0.012 3/74 PAK3, STAT5B, RASA1
Purine Metabolism 0.013 6/390 NME4, MYH6, KIF1B, PDE8B, RALBP1, GART
Integrin Signaling 0.015 5/209 WASL, PAK3, ASAP1, CTTN, FNBP1
Complement System 0.024 2/35 CFB, C2
Results are presented as log2 fold change.
{P was calculated by the Ingenuity System.
`Ratio: altered genes/total #genes in pathway.
doi:10.1371/journal.pone.0105099.t003
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associated with at least one of the main characteristics of CCH.
GLUL encodes for glutamine synthetase (GS) and is overexpressed
in ER positive luminal breast cancer subtypes and cell lines
compared to the basal subtype and cell lines [26]. We observed an
increase in GLUL expression which could possibly indicate a
progression of the epithelial CCH cells to a more ER positive
luminal carcinogenic phenotype. Increased levels of ERa observed
in CCH in vivo further indicate this possible progression. We also
observed elevated expression of one of the members of the kinase
subfamily WNK, WNK3. WNK3 promotes cell survival in HeLa
cells by delaying the apoptotic response in a caspase-3-dependent
manner [27]. The observed upregulated gene RASGRP3 is a Ras
activator that has been reported to be elevated in human
melanoma. Upregulation of RASGRP3 in melanocytes increased
the cell proliferation and made the cells tumorigenic in a mouse
xenograft model [28].
Moreover, we studied the miRNA expression profiles in one
patient who displayed invasive breast carcinoma in addition to
TDLU and CCH. The most prominent expression pattern was a
continuous decrease of expression or a sustained low level even in
the breast cancer sample. This is in line with earlier publications
illustrating downregulation of miRNAs in the progression towards
cancer and supports a general inhibitory function for miRNAs
[29]. Interestingly, approximately 16% of all miRNAs in the
Table 4. Gene expression analysis of epithelial CCH cells after co-culture with miR-132 overexpressing fibroblasts.
15 most upregulated genes
Fold change
(log2)
15 most
downregulated
genes Fold change (log2)
TFEC 5.90 NEK9 25.53
MARCH9 3.95 SLMAP 24.98
EPB41L3 3.92 DOCK5 24.96
DNAH11 3.60 CUL4B 24.80
NEK11 3.45 AP3B1 24.79
IFFO1 3.41 C1orf9 24.78
GLUL 3.40 PLEKHA5 24.72
TAF1C 3.40 ZZEF1 24.65
ACSS2 3.32 DHRS9 24.64
NCRNA00114 3.30 BZW2 24.61
WNK3 3,30 ULK2 24,49
TRMT2B 3,22 SLTM 24,44
PIWIL3 3,16 ADAMTS16 24,40
MAP2 3,16 POT1 24,31
RASGRP3 3,13 TBCK 24,30
Significantly upregulated pathways P{ Ratio` Genes
Cellular Effects of Sildenafil (Viagra) 0.001 5/151 SLC4A5, MYH2, MYH8, ITPR1, MYH1
Calcium Signaling 0.012 4/207 MYH2, MYH8, ITPR1, MYH1
Actin Cytoskeleton Signaling 0.023 4/238 MYH2, MYH8, NCKAP1L, MYH1
Hepatic Fibrosis/Hepatic Stellate Cell
Activation
0.035 3/147 MYH2, MYH8, MYH1
Assembly of RNA Polymerase I Complex 0.045 1/13 TAF1C
Tight Junction Signaling 0.046 3/164 MYH2, MYH8, MYH1
Significantly downregulated
pathways
P{ Ratio` Genes
Glycerophospholipid Metabolism 0.003 7/179 GPAM, PLCB2, BCHE, DGKB, DGKG, LPIN2, LYPLA1
Glycerolipid Metabolism 0.005 6/148 GPAM, DHRS9, LIPF, DGKB, DGKG, LPIN2
Phospholipid Degradation 0.008 5/93 PLCB2, DGKB, DGKG, LPIN2, LYPLA1
Cellular Effects of Sildenafil (Viagra) 0.022 6/151 MYH4, PLCB2, ADCY2, CACNA1E, PDE4C, MYH7
G-Protein Coupled Receptor Signaling 0.024 15/528 PLCB2, ADCY2, CCKAR, PDE4C, OPN1LW, SOS2,
PDE6C, GPR107, HTR6, RGS12, GPR64, CAMK2D,
DRD1, RXFP1, BAI1
cAMP-mediated signaling 0.025 8/218 ADCY2, CAMK2D, PDE4C, DRD1, PDE6C, CNGB1,
HTR6, RGS12
Purine Metabolism 0.033 9/392 ADCY2, POLR3B, PDE4C, KIF1B, NUDT9, PDE6C, MYH7,
REV3L, RALBP1
{P was calculated by the Ingenuity System.
`Ratio: altered genes/total #genes in pathway.
Results are presented as log2 fold change.
doi:10.1371/journal.pone.0105099.t004
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Figure 6. MiRNA expressions in TDLU, CCH and invasive breast cancer (IBC) in one case study. A) Expression levels of the selected
epithelial and stromal miRNA in TDLU, CCH and IBC. B) Line charts illustrating the distribution of fold change expressions for 663 miRNAs in the
epithelial and stromal compartment respectively.
doi:10.1371/journal.pone.0105099.g006
Figure 7. Summary of the reported study. The study included in vivo obtained epithelial and stromal miRNA expression signatures and
subsequent in vitro studies linking let-7c to proliferation, Myb and ERa. MiR-132 upregulation in fibroblasts affected several pathways as well as
greatly influenced co-cultured epithelial CCH cells.
doi:10.1371/journal.pone.0105099.g007
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epithelia had minor or no change between the different stages
whereas in the stroma this pattern was only observed in 4% of the
miRNAs, a possible indication of high stromal activity in early
precancerous lesions [30], underlining the significance of studying
these two compartments separately. We also observed that two
miRNAs in the different compartments had a more than 10-fold
increased expression in the invasive breast cancer sample; miR-
652 in the epithelial compartment and miR-484 in the stroma.
Decreased levels of miR-652 in blood was recently reported to be a
biomarker for luminal A-like breast tumours [31], and increased
expression of miR-484 has been observed in serum of early breast
cancer patients [32].
Taken together, the identified epithelial and stromal miRNA
changes may represent very early important changes in breast
cancer progression that might be targeted in future prevention
schedules.
Materials and Methods
Patient samples and cells
Specimens were obtained from women between 37–51 years of
age at the time for prophylactic mastectomy at Malmo¨ University
Hospital (1995–2008). Five patients were included in the
comparison between TDLU and CCH; two patients had BRCA1
and one had BRCA2 mutation without history of breast cancer,
one had both personal and family history of breast cancer without
identified mutation, and one had a therapeutic mastectomy due to
lobular invasive carcinoma and simultaneous contralateral pro-
phylactic mastectomy without family history of breast cancer. The
patient in the cancer progression case study had a family history of
breast cancer but no identified BRCA1/2 mutation. The patients’
written and verbal consent to participate in this study was
registered and the study was approved by the Ethics Committee at
Lund University, Sweden.
Human mammary CCH cells were derived from a clinical
sample after written informed consent and approved by the
Institutional Review Board for Baylor College of Medicine and
Affiliated Hospitals, Houston, Texas. Cells were cultured in
DMEM-F12 supplemented with 5% horse serum, cholera toxin
(100 ng/ml), hydrocortisone (0.5 mg/ml), insulin (10 mg/ml), EGF
(20 ng/ml) and 1% penicillin-streptomycin. Human breast cancer
cell line MCF-7 was purchased from ATCC and grown in DMEM
growth medium supplemented with 10% fetal bovine serum (FBS),
1% glutamine, 1x non-essential amino acids and 1x streptomycin
and penicillin. The normal human GFP-tagged immortalized
mammary fibroblasts cell line 218TGpp was a kind gift of
Professor Akira Orimo (Stromal-Tumour Interaction Group,
Paterson Institute for Cancer Research, The University of
Manchester) [33]. Cells were grown in DMEM supplemented
with 10% fetal bovine serum and 1% penicillin-streptomycin. All
cells were maintained at 37uC in a humified incubator (5% CO2).
Laser capture microdissection and RNA extraction
Epithelial cells and surrounding stroma from paired specimens
containing sufficient material of both normal TDLUs and CCH
were collected using laser capture microdissection (Leica Micro-
systems AB, Wetzlar, Germany). Tissue from both epithelial and
stromal compartments of TDLUs, CCH and invasive breast
cancer was collected from the cancer progression case study
patient. Total RNA was extracted using RecoverAll (Ambion/Life
Technologies, Carlsbad, CA) following the manufacturer’s in-
structions.
TaqMan MicroRNA Arrays
MiRNA expression profiles were obtained using TaqMan
MicroRNA Arrays v2.0 A and B (Applied Biosystems/Life
Technologies, Carlsbad, CA). 25 ng of total RNA was reverse-
transcribed using Megaplex Primer Pools A and B followed by
preamplification with Megaplex PreAmp Primers A and B. The
arrays were run on the 7900 HT Fast Real-Time System
according to manufacturer’s instructions (Applied Biosystems/Life
Technologies). Data analysis was performed using DataAssist v1.0
(Applied Biosystems/Life Technologies) and determined using the
comparative threshold cycle (Ct) method with RNU48 and
MammU6 as endogenous controls.
Quantitative real-time PCR
Individual TaqMan MicroRNA Assays (Applied Biosystems/
Life Technologies) were used for quantification of let-7c, miR-132
and the endogenous controls RNU48 and MammU6 according to
the manufacturer’s instructions. SDHA, UBC, and YWHAZ were
used as reference genes for Myb and ERa quantification. Total
RNA was extracted using the miRNeasy kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions with the
exception of replacing chloroform with 70 ml BCP (1-bromo-3-
chloro-propan). For miRNA quantification, 500 ng of RNA was
reverse-transcribed using Megaplex Primer Pool A. For mRNA
quantification, 2 mg of RNA was converted to cDNA using High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems/
Life Technologies). qRT-PCR was carried out using 7300 Real
Time PCR System (Applied Biosystems/Life Technologies). The
Ct method was used for calculation of gene expression.
Transfections
Cells were transfected with 20 nM miRNA Inhibitor (Exiqon)
or 25 nM miRIDIAN miRNA mimics (Dharmacon/Thermo
Fisher Scientific, Waltham, MA) or corresponding non-targeting
control oligonucleotides of the same length, according to the
manufacturer’s instructions using Lipofectamine 2000 (Invitro-
gen/Life Technologies, Carlsbad, CA) in Opti-MEM medium
depleted from serum and penicillin-streptomycin. The medium
was changed to serum-containing medium 5 h after transfection.
Cell proliferation assays
Cell number was measured by counting cells 48 h after
transfection using a Bu¨rker chamber and by using the Moxi
Automated Cell Counter (ORFLO Technologies).
Cell proliferation was monitored using Alamar Blue (Invitro-
gen). Cells were seeded out in 96 well plates at 10000 cells/well)
24 h prior to transfection. Cell viability was measured after 48 h
by adding 2% Alamar blue and fluorescence was read at 544/
590 nm after 1 h incubation.
Flow cytometry for cell cycle and apoptosis analysis
Cell cycle analysis was performed using propidium iodide as
previously described [34].
For apoptosis analysis, cells were stained with Annexin V-FITC
and 7AAD (BD Pharmingen, San Jose, CA) to analyse both early
(Annexin V+/7AAD–) cells and late (Annexin V+/7AAD+)
apoptotic cells, and analyzed with BD Accuri C6 Flow Cytometer
(BD Biosciences, San Jose, CA). Data analyses were performed
with FlowJo (FlowJo, Ashland, OR).
Immunohistochemistry and western blot
Immunohistochemistry was performed using Dako’s Autostai-
nerplus with the EnVisionFlex High pH-kit (DAKO, Glostrup,
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Denmark) with the following antibodies: CK5 (Novocastra,
Wetzlar, Germany), CK14 (Novocastra), CK17 (DAKO), CK18
(DAKO), CK19 (DAKO), CK20 (DAKO), vimentin (DAKO),
ERa (DAKO), Myb (Epitomics, San Francisco, CA). Western blot
was performed as previously described [35] using the following
primary antibodies: caspase 3 (Cell Signaling Technology,
Danvers, MA), b-actin (Santa Cruz Biotechnology, Santa Cruz,
CA), Myb (Merck Millipore clone 1-1, Darmstadt, Germany),
ERa (DAKO).
Co-cultivation of cells and fluorescence-activated cell
sorting (FACS)
GFP-tagged fibroblasts were transfected with either control or
miR-132 mimics. Cells were harvested 24 h after transfection and
equal number of fibroblasts and low passage CCH cells were
seeded together in CCH cell medium and incubated for 48 h.
Cells were labelled with 7AAD in order to sort out live cells before
the GFP positive fibroblasts and GFP negative CCH cells were
separately collected using FACS followed by RNA extraction from
the CCH cells.
CGH analysis, statistical methods and gene expression
profiling
CGH analysis was performed on the Agilent G3 Human 161 m
CGH Microarray by ATLAS Biolabs GmbH in Berlin, Germany.
The list of potentially significantly altered miRNAs in the epithelial
cells and statistical significance to all in vitro experiments were
calculated using two-sided Student’s T-tests. The R package
qvalue was used to compute the false discovery rate [36]. The
Affymetrix GeneChip Human Gene 1.0 ST Arrays were
performed by AROS Applied Biotechnology A/S (Aarhus,
Denmark) and analysed with R, Bioconductor and Ingenuity
Systems (Redwood City, CA). The RMA was used to normalise
and summarise the expression values at the probeset level [37].
Probesets were mapped to genes using the Bioconductor package
annmap to position probesets relative to Ensembl version 60
annotations [38]. The R package Limma was used to find
differentially expressed genes [39] and Ingenuity to find the
enriched pathways from the differentially expressed gene lists. The
raw array data is located at the GEO database with the accession
number: GSE46199.
Supporting Information
Figure S1 CGH analysis of CCH cells.
(TIF)
Figure S2 Validation of miRNA microarray results. The
expression of let-7c was analysed in microdissected epithelial tissue
from one additional patient using qRT-PCR.
(TIF)
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